ClinicalTrials.gg
CompletedNCT02625207Updated Apr 17, 2017Results posted

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

A Phase 1 interventional study of Maraviroc (Part 1) and Maraviroc (Part 2) in Healthy Subjects, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-04-17.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This will be an open-label, parallel group, multiple dose study in approximately 48 healthy male or female subjects of African American and Caucasian self-reported race, to assess the effect of CYP3A5 genotype on the PK of MVC and CYP3A5-derived metabolites. Maraviroc and CYP3A5-derived metabolite PK will also be compared between African-Americans and Caucasians in subjects carrying two copies of the dysfunctional CYP3A5 alleles (*3, *6, and/or *7).

Read the detailed description

This will be an open-label, parallel group, multiple dose study in approximately 48 healthy male or female subjects of African American and Caucasian self-reported race, to assess the effect of CYP3A5 genotype on the PK of MVC and CYP3A5-derived metabolites. Maraviroc and CYP3A5-derived metabolite PK will also be compared between African-Americans and Caucasians in subjects carrying two copies of the dysfunctional CYP3A5 alleles (*3, *6, and/or *7).

Dysfunctional genetic variants for CYP3A5, CYP3A4 and SLCO1B1 will be genotyped for subjects who participate in the pre-screening. Subjects who meet the inclusion/exclusion criteria for study participation will be placed into the study cohorts based on race and the number of functional (*1) and dysfunctional CYP3A5 alleles (*3, *6, and *7) CYP3A5 alleles.

Cohort 1 (n=12; African-American): No CYP3A5*1 alleles (poor metabolizer). Cohort 2 (n=12; African-American): One CYP3A5*1 allele (intermediate metabolizer).

Cohort 3 (n=12; African-American): Two CYP3A5*1 alleles (extensive metabolizer).

Cohort 4 (n=12; Caucasian): No CYP3A5*1 alleles (poor metabolizer).

Study Treatments:

Part 1 Days 1-5: Maraviroc 300 mg BID in fasted state (AM dose only on Day 5). Part 2 (Cohorts 1 and 3 only) Days 1-10: Maraviroc 150 mg QD plus darunavir/cobicistat 800/150 mg QD with food.

Pharmacokinetics of MVC, PF-6857639, PF-6857640 and other hydroxylated metabolites with formation mediated by CYP3A5 (if present) will be assessed on Part 1, Day 5 and Part 2, Days 10-11. Blood samples will be collected for a full PK profile.

Subjects will be confined to the Clinical Research Unit (CRU) the day prior to dosing on Day 1 (Day 0) and discharged on Part 1, Day 6 and on Part 2, Day 11 (Cohorts 1 and 3 only). Subjects enrolled into Cohorts 1 and 3 may be confined to the CRU without the need to be discharged between Part 1 and Part 2.

02

Conditions studied

  • Healthy Subjects

Keywords

  • Maraviroc, CYP3A5, pharmacokinetics, pharmacogenomics
03

In context

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs)
  • Healthy female subjects and/or male subjects of African-American/Black or Caucasian race

Exclusion criteria

Exclusion Criteria:

  • History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males
  • Treatment with an drug within 30 days
  • Screening supine blood pressure \<90 or >/=140 mm Hg (systolic) or \<60 or >/= 90 mm Hg (diastolic), following at least 5 minutes of supine rest
  • Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
  • Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day
  • Subjects who have a *22 allele and/or have a SLCO1B1 *5 or *15 allele
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Cohort 1

    African-Americans with No CYP3A5\*1 alleles (poor metabolizer)

    Drug: Maraviroc (Part 1) · Drug: Maraviroc (Part 2) · Drug: Darunavir/cobicistat (Part 2)

  • Experimental
    Cohort 2

    African-Americans with One CYP3A5\*1 allele (intermediate metabolizer)

    Drug: Maraviroc (Part 1)

  • Experimental
    Cohort 3

    African-Americans with Two CYP3A5\*1 alleles (extensive metabolizer)

    Drug: Maraviroc (Part 1) · Drug: Maraviroc (Part 2) · Drug: Darunavir/cobicistat (Part 2)

  • Experimental
    Cohort 4

    Caucasians with No CYP3A5\*1 alleles (poor metabolizer)

    Drug: Maraviroc (Part 1)

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc

    AUC (0-12) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

  2. Part 2: Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) of Maraviroc

    AUC (0-24) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours post-dose.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10

  3. Part 1: Metabolite to Parent Ratio for Area Under the Concentration-Time Curve From Time 0 to 12 Hours for Maraviroc and Its Metabolites (MRAUC12)

    MRAUC12 is the ratio of AUC12 of maraviroc to AUC12 of maraviroc's metabolites. Metabolites of Maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573. AUC12 is the area under the plasma concentration-time profile from time 0 to 12 hours post-dose.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

Secondary outcomes

  1. Part 1: Average Plasma Concentration (Cavg) of Maraviroc

    Cavg is the average plasma concentration of maraviroc during the 0 to 12 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 12 hours (AUC \[0-12\]) divided by 12.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

  2. Part 2: Average Plasma Concentration (Cavg) of Maraviroc

    Cavg is the average plasma concentration of maraviroc during the 0 to 24 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 24 hours (AUC \[0-24\]) divided by 24.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10

  3. Part 1: Maximum Observed Plasma Concentration (Cmax) of Maraviroc

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

  4. Part 2: Maximum Observed Plasma Concentration (Cmax) of Maraviroc

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10

  5. Part 1: Plasma Concentration of Maraviroc at 12 Hours Post-dose

    Time frame: 12 hours post-dose on Day 5

  6. Part 2: Plasma Concentration of Maraviroc at 24 Hours Post-dose

    Time frame: 24 hours post-dose on Day 10

  7. Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

  8. Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10

  9. Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Metabolites of Maraviroc

    AUC (0-12) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose. Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

  10. Part 1: Average Plasma Concentration (Cav) of Metabolites of Maraviroc

    Cavg is the average plasma concentration of metabolites of maraviroc during the 0 to 12 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 12 hours (AUC \[0-12\]) divided by 12. Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

  11. Part 1: Maximum Observed Plasma Concentration (Cmax) of Metabolites of Maraviroc

    Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

  12. Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metabolites of Maraviroc

    Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

    Time frame: Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5

  13. Part 1: Plasma Concentration of Metabolites of Maraviroc at 12 Hour Post-dose

    Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

    Time frame: 12 hour post-dose on Day 5

  14. Part 1: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 days that were absent before treatment or that worsened relative to pre-treatment state.

    Time frame: Baseline up to end of study (up to 6 days)

  15. Part 2: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 11 days that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to end of study (up to 11 days)

  16. Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities

    Criteria for clinically significant vital sign abnormalities included supine/sitting pulse rate of less than (\<) 40 beats per minute (bpm) or greater than (\>)120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine systolic blood pressure (SBP) and standing SBP of \<90 millimeter of mercury (mm Hg), greater than or equal to (\>=) 30 mm Hg, supine diastolic blood pressure (DBP) and standing DBP of \<50 mm Hg, \>=20 mm Hg.

    Time frame: Baseline up to Day 6

  17. Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities

    Criteria for clinically significant vital sign abnormalities included supine/sitting pulse rate of \<40 bpm or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine SBP and standing SBP of \<90 mm Hg, \>=30 mm Hg, supine DBP and standing DBP of \<50 mm Hg, \>=20 mm Hg.

    Time frame: Baseline up to Day 11

  18. Part 1: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities

    Criteria for ECG abnormalities: Maximum PR interval of \>=300 milliseconds (msec), maximum QRS interval \>=140 msec, maximum QTCF interval (Fridericia's correction) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, maximum increase of \>=25 percent for baseline values of \>200 msec and \>=50 percent for baseline values of less than or equal to (\<=) 200 msec for PR interval, maximum increase from baseline of \>=50 percent for QRS interval, maximum increase from baseline of \>=30 msec to \<60 msec and maximum increase from baseline of \>60 msec in QTCF interval (Fridericia's Correction).

    Time frame: Baseline up to Day 6

  19. Part 2: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities

    Criteria for ECG abnormalities: Maximum PR interval of \>=300 msec, maximum QRS interval \>=140 msec, maximum QTCF interval (Fridericia's correction) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, maximum increase of \>=25 percent for baseline values of \>200 msec and \>=50 percent for baseline values of \<=200 msec for PR interval, maximum increase from baseline of \>=50 percent for QRS interval, maximum increase from baseline of \>=30 msec to \<60 msec and maximum increase from baseline of \>60 msec in QTCF interval (Fridericia's Correction).

    Time frame: Baseline up to Day 11

  20. Part 1: Number of Participants With Laboratory Abnormalities

    Criteria: Hemoglobin; hematocrit; red blood cell count: \<0.8\*lower limit of normal, (LLN), mean corpuscular volume; mean corpuscular hemoglobin concentration; mean platelet volume:\<0.9\*LLN or \>1.1\* upper limit of normal (ULN), platelet: \<0.5\*LLN or \>1.75\*ULN, white blood cells \<0.6\*LLN or \>1.5\*ULN, lymphocyte; neutrophil: \<0.8\*LLN or \>1.2\*ULN, basophil; eosinophil; monocyte:\>1.2\*ULN, bilirubin (total, direct, indirect) \>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase:\>3.0\*ULN, total protein; albumin:\<0.8\*LLN or \>1.2\*ULN; creatinine: \>1.3\*ULN, uric acid\>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride; calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN, glucose \<0.6\*LLN or \>1.5\*ULN, urine specific gravity \<1.003, urine pH \<4.5 or \>8, urine glucose or ketones (qualitative) \>=1, urine protein; urine blood/hemoglobin \>=1, urobilinogen; bilirubin; nitrite; leukocyte esterase \>=1.

    Time frame: Baseline up to Day 6

  21. Part 2: Number of Participants With Laboratory Abnormalities

    Criteria: Hemoglobin; hematocrit; red blood cell count: \<0.8\*LLN, mean corpuscular volume; mean corpuscular hemoglobin concentration; mean platelet volume: \<0.9\*LLN or \>1.1\*ULN, platelet: \<0.5\*LLN or \>1.75\*ULN, white blood cells \<0.6\*LLN or \>1.5\*ULN, lymphocyte; neutrophil: \<0.8\*LLN or \>1.2\*ULN, basophil; eosinophil; monocyte: \>1.2\*ULN, bilirubin (total, direct, indirect) \>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase: \>3.0\*ULN, total protein; albumin: \<0.8\*LLN or \>1.2\*ULN; creatinine: \>1.3\*ULN, uric acid \>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride; calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN, glucose \<0.6\*LLN or \>1.5\*ULN, urine specific gravity \<1.003, urine pH \<4.5 or \>8, urine glucose or ketones (qualitative) \>=1, urine protein; urine blood/hemoglobin \>=1, urobilinogen; bilirubin; nitrite; leukocyte esterase \>=1.

    Time frame: Baseline up to Day 11

07

Results

Posted Apr 17, 2017
Limitations and caveats
As per change in planned analysis, calculation of metabolite PK parameters and statistical analyses were not conducted in Part 2, since substantial number of PK samples were below limit of quantitation, considered as non-reliable by investigator.

Participant flow

Part 1 (6 Days)
Participant flow — Part 1 (6 Days)
MilestonePart 1 and Part 2: Cohort 1 -No CYP3A5*1 AllelesPart 1: Cohort 2 - One CYP3A5*1 AllelePart 1 and 2: Cohort 3 - Two CYP3A5*1 AllelesPart 1: Cohort 4 - No CYP3A5*1 Alleles
Started11121212
Completed11121212
Not completed0000
Part 2 (11 Days)
Participant flow — Part 2 (11 Days)
MilestonePart 1 and Part 2: Cohort 1 -No CYP3A5*1 AllelesPart 1: Cohort 2 - One CYP3A5*1 AllelePart 1 and 2: Cohort 3 - Two CYP3A5*1 AllelesPart 1: Cohort 4 - No CYP3A5*1 Alleles
Started110120
Completed110120
Not completed0000

Outcome measures

PrimaryPart 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc

AUC (0-12) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc
nanogram*hour per milliliter (ng*hr/mL)Cohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Maraviroc3441 ± 242954 ± 232181 ± 272947 ± 23
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.1318 · Adjusted geometric mean ratio: 116.73 · 90% CI 98.55 to 138.26
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 2- One CYP3A5*1 Allele · Mixed Models Analysis · p = 0.1369 · Adjusted geometric mean ratio: 85.85 · 90% CI 72.48 to 101.68
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = < 0.0001 · Adjusted geometric mean ratio: 63.38 · 90% CI 53.51 to 75.07
  • Cohort 2- One CYP3A5*1 Allele vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0036 · Adjusted geometric mean ratio: 73.83 · 90% CI 62.57 to 87.13
  • Cohort 3- Two CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0038 · Adjusted geometric mean ratio: 73.99 · 90% CI 62.70 to 87.31
PrimaryPart 2: Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) of Maraviroc

AUC (0-24) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours post-dose.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10
Reported as:
Geometric mean · ng*hr/mL
Part 2: Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) of Maraviroc
ng*hr/mLCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
Part 2: Area Under The Plasma Concentration-Time Curve From Time 0 to 24 Hours (AUC [0-24]) of Maraviroc4413 ± 203645 ± 25
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0531 · Adjusted geometric mean ratio: 82.59 · 90% CI 70.33 to 96.98
PrimaryPart 1: Metabolite to Parent Ratio for Area Under the Concentration-Time Curve From Time 0 to 12 Hours for Maraviroc and Its Metabolites (MRAUC12)

MRAUC12 is the ratio of AUC12 of maraviroc to AUC12 of maraviroc's metabolites. Metabolites of Maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573. AUC12 is the area under the plasma concentration-time profile from time 0 to 12 hours post-dose.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Geometric mean · ratio
Part 1: Metabolite to Parent Ratio for Area Under the Concentration-Time Curve From Time 0 to 12 Hours for Maraviroc and Its Metabolites (MRAUC12)
ratioCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
PF-68576390.02172 ± 310.03564 ± 270.04312 ± 320.01585 ± 24
PF-68576400.02577 ± 110.02621 ± 270.02797 ± 320.02338 ± 14
PF-069275720.02766 ± 190.02908 ± 350.02795 ± 370.02774 ± 29
PF-069275730.02048 ± 140.02427 ± 380.02040 ± 270.02099 ± 21
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0106 · Adjusted geometric mean ratio: 137.07 · 90% CI 112.40 to 167.15
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 2- One CYP3A5*1 Allele · Mixed Models Analysis · p = 0.0001 · Adjusted geometric mean ratio: 164.06 · 90% CI 134.54 to 200.06
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = < 0.0001 · Adjusted geometric mean ratio: 198.49 · 90% CI 162.77 to 242.05
  • Cohort 2- One CYP3A5*1 Allele vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.1061 · Adjusted geometric mean ratio: 120.99 · 90% CI 99.65 to 146.90
  • Cohort 3- Two CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = <0.0001 · Adjusted geometric mean ratio: 272.07 · 90% CI 224.08 to 330.33
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.3081 · Adjusted geometric mean ratio: 110.22 · 90% CI 94.05 to 129.18
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 2- One CYP3A5*1 Allele · Mixed Models Analysis · p = 0.8583 · Adjusted geometric mean ratio: 101.71 · 90% CI 86.79 to 119.20
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.3913 · Adjusted geometric mean ratio: 108.52 · 90% CI 92.60 to 127.17
  • Cohort 2- One CYP3A5*1 Allele vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.4866 · Adjusted geometric mean ratio: 106.69 · 90% CI 91.36 to 124.60
  • Cohort 3- Two CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0590 · Adjusted geometric mean ratio: 119.61 · 90% CI 102.42 to 139.69
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.9816 · Adjusted geometric mean ratio: 99.70 · 90% CI 80.47 to 123.53
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 2- One CYP3A5*1 Allele · Mixed Models Analysis · p = 0.6974 · Adjusted geometric mean ratio: 105.12 · 90% CI 84.84 to 130.24
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.9363 · Adjusted geometric mean ratio: 101.03 · 90% CI 81.54 to 125.18
  • Cohort 2- One CYP3A5*1 Allele vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.7520 · Adjusted geometric mean ratio: 96.11 · 90% CI 77.94 to 118.52
  • Cohort 3- Two CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.9536 · Adjusted geometric mean ratio: 100.73 · 90% CI 81.69 to 124.22
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.8241 · Adjusted geometric mean ratio: 97.60 · 90% CI 81.28 to 117.18
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 2- One CYP3A5*1 Allele · Mixed Models Analysis · p = 0.1261 · Adjusted geometric mean ratio: 118.50 · 90% CI 98.69 to 142.28
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.9708 · Adjusted geometric mean ratio: 99.60 · 90% CI 82.95 to 119.59
  • Cohort 2- One CYP3A5*1 Allele vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.1099 · Adjusted geometric mean ratio: 84.05 · 90% CI 70.29 to 100.52
  • Cohort 3- Two CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.7913 · Adjusted geometric mean ratio: 97.21 · 90% CI 81.29 to 116.25
SecondaryPart 1: Average Plasma Concentration (Cavg) of Maraviroc

Cavg is the average plasma concentration of maraviroc during the 0 to 12 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 12 hours (AUC \[0-12\]) divided by 12.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Part 1: Average Plasma Concentration (Cavg) of Maraviroc
nanogram per milliliter (ng/mL)Cohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
Part 1: Average Plasma Concentration (Cavg) of Maraviroc286.8 ± 24246.2 ± 23181.6 ± 27245.8 ± 23
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.1338 · Adjusted geometric mean ratio: 116.65 · 90% CI 98.47 to 138.18
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 2- One CYP3A5*1 Allele · Mixed Models Analysis · p = 0.1370 · Adjusted geometric mean ratio: 85.84 · 90% CI 72.46 to 101.68
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = < 0.0001 · Adjusted geometric mean ratio: 63.34 · 90% CI 53.47 to 75.04
  • Cohort 2- One CYP3A5*1 Allele vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0036 · Adjusted geometric mean ratio: 73.79 · 90% CI 62.53 to 87.09
  • Cohort 3- Two CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0037 · Adjusted geometric mean ratio: 73.89 · 90% CI 62.61 to 87.20
SecondaryPart 2: Average Plasma Concentration (Cavg) of Maraviroc

Cavg is the average plasma concentration of maraviroc during the 0 to 24 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 24 hours (AUC \[0-24\]) divided by 24.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10
Reported as:
Geometric mean · ng/mL
Part 2: Average Plasma Concentration (Cavg) of Maraviroc
ng/mLCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
Part 2: Average Plasma Concentration (Cavg) of Maraviroc184.1 ± 20151.7 ± 25
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0507 · Adjusted geometric mean ratio: 82.42 · 90% CI 70.20 to 96.77
SecondaryPart 1: Maximum Observed Plasma Concentration (Cmax) of Maraviroc
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Observed Plasma Concentration (Cmax) of Maraviroc
ng/mLCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
Part 1: Maximum Observed Plasma Concentration (Cmax) of Maraviroc863.9 ± 29754.0 ± 29529.0 ± 34731.0 ± 33
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.1997 · Adjusted geometric mean ratio: 118.19 · 90% CI 95.26 to 146.63
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 2- One CYP3A5*1 Allele · Mixed Models Analysis · p = 0.2947 · Adjusted geometric mean ratio: 87.28 · 90% CI 70.34 to 108.28
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0004 · Adjusted geometric mean ratio: 61.23 · 90% CI 49.35 to 75.97
  • Cohort 2- One CYP3A5*1 Allele vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0071 · Adjusted geometric mean ratio: 70.16 · 90% CI 56.81 to 86.63
  • Cohort 3- Two CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0135 · Adjusted geometric mean ratio: 72.37 · 90% CI 58.60 to 89.36
SecondaryPart 2: Maximum Observed Plasma Concentration (Cmax) of Maraviroc
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10
Reported as:
Geometric mean · ng/mL
Part 2: Maximum Observed Plasma Concentration (Cmax) of Maraviroc
ng/mLCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
Part 2: Maximum Observed Plasma Concentration (Cmax) of Maraviroc633.6 ± 37432.9 ± 53
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0505 · Adjusted geometric mean ratio: 68.32 · 90% CI 49.81 to 93.71
SecondaryPart 1: Plasma Concentration of Maraviroc at 12 Hours Post-dose
Time frame:
12 hours post-dose on Day 5
Reported as:
Geometric mean · ng/mL
Part 1: Plasma Concentration of Maraviroc at 12 Hours Post-dose
ng/mLCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
Part 1: Plasma Concentration of Maraviroc at 12 Hours Post-dose59.84 ± 3663.09 ± 2745.32 ± 3563.10 ± 24
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.6761 · Adjusted geometric mean ratio: 94.83 · 90% CI 76.70 to 117.24
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 2- One CYP3A5*1 Allele · Mixed Models Analysis · p = 0.6771 · Adjusted geometric mean ratio: 105.43 · 90% CI 85.28 to 130.35
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0331 · Adjusted geometric mean ratio: 75.74 · 90% CI 61.26 to 93.64
  • Cohort 2- One CYP3A5*1 Allele vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0104 · Adjusted geometric mean ratio: 71.84 · 90% CI 58.38 to 88.40
  • Cohort 3- Two CYP3A5*1 Alleles vs Cohort 4- No CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.0104 · Adjusted geometric mean ratio: 71.82 · 90% CI 58.37 to 88.39
SecondaryPart 2: Plasma Concentration of Maraviroc at 24 Hours Post-dose
Time frame:
24 hours post-dose on Day 10
Reported as:
Geometric mean · ng/mL
Part 2: Plasma Concentration of Maraviroc at 24 Hours Post-dose
ng/mLCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
Part 2: Plasma Concentration of Maraviroc at 24 Hours Post-dose56.56 ± 2056.34 ± 30
Statistical analysis
  • Cohort 1- No CYP3A5*1 Alleles vs Cohort 3- Two CYP3A5*1 Alleles · Mixed Models Analysis · p = 0.9713 · Adjusted geometric mean ratio: 99.62 · 90% CI 83.07 to 119.45
SecondaryPart 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Median · hour
Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc
hourCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc3.00 (2.00 to 4.00)2.00 (0.500 to 3.00)2.00 (0.517 to 4.00)2.01 (0.500 to 3.05)
SecondaryPart 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc
Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours post-dose on Day 10
Reported as:
Median · hour
Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc
hourCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
Part 2: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Maraviroc3.00 (1.07 to 6.00)3.02 (1.00 to 6.02)
SecondaryPart 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Metabolites of Maraviroc

AUC (0-12) is the area under the plasma concentration versus time curve from time zero (pre-dose) to 12 hours post-dose. Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Geometric mean · ng*hr/mL
Part 1: Area Under The Plasma Concentration-Time Curve From Time 0 to 12 Hours (AUC [0-12]) of Metabolites of Maraviroc
ng*hr/mLCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
PF-685763977.09 ± 32108.7 ± 4496.98 ± 2948.24 ± 32
PF-685764091.42 ± 2279.92 ± 4462.86 ± 2671.15 ± 23
PF-0692757298.14 ± 2388.63 ± 4962.80 ± 2884.32 ± 33
PF-0692757372.67 ± 2873.92 ± 5345.86 ± 2763.88 ± 28
SecondaryPart 1: Average Plasma Concentration (Cav) of Metabolites of Maraviroc

Cavg is the average plasma concentration of metabolites of maraviroc during the 0 to 12 hour time period. It was calculated as area under the plasma concentration-time curve from 0 to 12 hours (AUC \[0-12\]) divided by 12. Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Geometric mean · ng/mL
Part 1: Average Plasma Concentration (Cav) of Metabolites of Maraviroc
ng/mLCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
PF-68576396.420 ± 329.049 ± 448.074 ± 294.018 ± 32
PF-68576407.615 ± 226.658 ± 445.239 ± 265.930 ± 23
PF-069275728.179 ± 237.383 ± 495.232 ± 287.029 ± 33
PF-069275736.056 ± 286.165 ± 533.821 ± 275.323 ± 28
SecondaryPart 1: Maximum Observed Plasma Concentration (Cmax) of Metabolites of Maraviroc

Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Geometric mean · ng/mL
Part 1: Maximum Observed Plasma Concentration (Cmax) of Metabolites of Maraviroc
ng/mLCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
PF-685763918.14 ± 2324.18 ± 5520.52 ± 3411.22 ± 37
PF-685764021.95 ± 2818.96 ± 5615.00 ± 3016.48 ± 28
PF-0692757222.88 ± 1820.67 ± 5815.31 ± 3219.91 ± 35
PF-0692757317.39 ± 3217.64 ± 6610.86 ± 3415.27 ± 35
SecondaryPart 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metabolites of Maraviroc

Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

Time frame:
Pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12 hours post-dose on Day 5
Reported as:
Median · hour
Part 1: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Metabolites of Maraviroc
hourCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
PF-68576393.00 (1.00 to 4.00)2.00 (0.500 to 3.00)2.00 (0.533 to 4.00)3.00 (0.500 to 4.00)
PF-68576403.00 (1.00 to 4.00)2.00 (0.500 to 3.02)2.00 (0.533 to 4.00)3.00 (1.00 to 4.00)
PF-069275723.00 (1.00 to 4.00)2.00 (0.500 to 3.00)1.52 (0.500 to 4.00)3.00 (1.00 to 4.00)
PF-069275733.00 (1.00 to 4.00)2.00 (0.500 to 3.00)2.00 (0.567 to 4.00)3.00 (1.00 to 4.00)
SecondaryPart 1: Plasma Concentration of Metabolites of Maraviroc at 12 Hour Post-dose

Metabolites of maraviroc included PF-6857639, PF-6857640, PF-06927572 and PF-06927573.

Time frame:
12 hour post-dose on Day 5
Reported as:
Geometric mean · ng/mL
Part 1: Plasma Concentration of Metabolites of Maraviroc at 12 Hour Post-dose
ng/mLCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
PF-68576390.6249 ± 73992.748 ± 432.226 ± 320.9213 ± 38
PF-68576400.6290 ± 71641.658 ± 401.134 ± 291.300 ± 33
PF-069275720.6242 ± 70511.752 ± 451.071 ± 291.385 ± 40
PF-069275730.5396 ± 62831.629 ± 550.8550 ± 261.175 ± 32
SecondaryPart 1: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 days that were absent before treatment or that worsened relative to pre-treatment state.

Time frame:
Baseline up to end of study (up to 6 days)
Reported as:
Number · participants
Part 1: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
AEs3003
SAEs0000
SecondaryPart 2: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 11 days that were absent before treatment or that worsened relative to pretreatment state.

Time frame:
Baseline up to end of study (up to 11 days)
Reported as:
Number · participants
Part 2: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
AEs21
SAEs00
SecondaryPart 1: Number of Participants With Clinically Significant Vital Sign Abnormalities

Criteria for clinically significant vital sign abnormalities included supine/sitting pulse rate of less than (\<) 40 beats per minute (bpm) or greater than (\>)120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine systolic blood pressure (SBP) and standing SBP of \<90 millimeter of mercury (mm Hg), greater than or equal to (\>=) 30 mm Hg, supine diastolic blood pressure (DBP) and standing DBP of \<50 mm Hg, \>=20 mm Hg.

Time frame:
Baseline up to Day 6
Reported as:
Number · participants
Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities
participantsCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
Part 1: Number of Participants With Clinically Significant Vital Sign Abnormalities0000
SecondaryPart 2: Number of Participants With Clinically Significant Vital Sign Abnormalities

Criteria for clinically significant vital sign abnormalities included supine/sitting pulse rate of \<40 bpm or \>120 bpm, standing pulse rate of \<40 bpm or \>140 bpm, supine SBP and standing SBP of \<90 mm Hg, \>=30 mm Hg, supine DBP and standing DBP of \<50 mm Hg, \>=20 mm Hg.

Time frame:
Baseline up to Day 11
Reported as:
Number · participants
Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities
participantsCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
Part 2: Number of Participants With Clinically Significant Vital Sign Abnormalities00
SecondaryPart 1: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities

Criteria for ECG abnormalities: Maximum PR interval of \>=300 milliseconds (msec), maximum QRS interval \>=140 msec, maximum QTCF interval (Fridericia's correction) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, maximum increase of \>=25 percent for baseline values of \>200 msec and \>=50 percent for baseline values of less than or equal to (\<=) 200 msec for PR interval, maximum increase from baseline of \>=50 percent for QRS interval, maximum increase from baseline of \>=30 msec to \<60 msec and maximum increase from baseline of \>60 msec in QTCF interval (Fridericia's Correction).

Time frame:
Baseline up to Day 6
Reported as:
Number · participants
Part 1: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
participantsCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
Part 1: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities0000
SecondaryPart 2: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities

Criteria for ECG abnormalities: Maximum PR interval of \>=300 msec, maximum QRS interval \>=140 msec, maximum QTCF interval (Fridericia's correction) of 450 to \<480 msec, 480 to \<500 msec and \>=500 msec, maximum increase of \>=25 percent for baseline values of \>200 msec and \>=50 percent for baseline values of \<=200 msec for PR interval, maximum increase from baseline of \>=50 percent for QRS interval, maximum increase from baseline of \>=30 msec to \<60 msec and maximum increase from baseline of \>60 msec in QTCF interval (Fridericia's Correction).

Time frame:
Baseline up to Day 11
Reported as:
Number · participants
Part 2: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities
participantsCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
Part 2: Number of Participants With 12-Lead Electrocardiogram (ECG) Abnormalities00
SecondaryPart 1: Number of Participants With Laboratory Abnormalities

Criteria: Hemoglobin; hematocrit; red blood cell count: \<0.8\*lower limit of normal, (LLN), mean corpuscular volume; mean corpuscular hemoglobin concentration; mean platelet volume:\<0.9\*LLN or \>1.1\* upper limit of normal (ULN), platelet: \<0.5\*LLN or \>1.75\*ULN, white blood cells \<0.6\*LLN or \>1.5\*ULN, lymphocyte; neutrophil: \<0.8\*LLN or \>1.2\*ULN, basophil; eosinophil; monocyte:\>1.2\*ULN, bilirubin (total, direct, indirect) \>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase:\>3.0\*ULN, total protein; albumin:\<0.8\*LLN or \>1.2\*ULN; creatinine: \>1.3\*ULN, uric acid\>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride; calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN, glucose \<0.6\*LLN or \>1.5\*ULN, urine specific gravity \<1.003, urine pH \<4.5 or \>8, urine glucose or ketones (qualitative) \>=1, urine protein; urine blood/hemoglobin \>=1, urobilinogen; bilirubin; nitrite; leukocyte esterase \>=1.

Time frame:
Baseline up to Day 6
Reported as:
Number · participants
Part 1: Number of Participants With Laboratory Abnormalities
participantsCohort 1- No CYP3A5*1 AllelesCohort 2- One CYP3A5*1 AlleleCohort 3- Two CYP3A5*1 AllelesCohort 4- No CYP3A5*1 Alleles
Part 1: Number of Participants With Laboratory Abnormalities1502
SecondaryPart 2: Number of Participants With Laboratory Abnormalities

Criteria: Hemoglobin; hematocrit; red blood cell count: \<0.8\*LLN, mean corpuscular volume; mean corpuscular hemoglobin concentration; mean platelet volume: \<0.9\*LLN or \>1.1\*ULN, platelet: \<0.5\*LLN or \>1.75\*ULN, white blood cells \<0.6\*LLN or \>1.5\*ULN, lymphocyte; neutrophil: \<0.8\*LLN or \>1.2\*ULN, basophil; eosinophil; monocyte: \>1.2\*ULN, bilirubin (total, direct, indirect) \>1.5\*ULN, aspartate aminotransferase; alanine aminotransferase; alkaline phosphatase: \>3.0\*ULN, total protein; albumin: \<0.8\*LLN or \>1.2\*ULN; creatinine: \>1.3\*ULN, uric acid \>1.2\*ULN, sodium\<0.95\*LLN or \>1.05\*ULN, potassium; chloride; calcium; bicarbonate:\<0.9\*LLN or \>1.1\*ULN, glucose \<0.6\*LLN or \>1.5\*ULN, urine specific gravity \<1.003, urine pH \<4.5 or \>8, urine glucose or ketones (qualitative) \>=1, urine protein; urine blood/hemoglobin \>=1, urobilinogen; bilirubin; nitrite; leukocyte esterase \>=1.

Time frame:
Baseline up to Day 11
Reported as:
Number · participants
Part 2: Number of Participants With Laboratory Abnormalities
participantsCohort 1- No CYP3A5*1 AllelesCohort 3- Two CYP3A5*1 Alleles
Part 2: Number of Participants With Laboratory Abnormalities13

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohort 1- No CYP3A5*1 Alleles—0/11 (0%)3/11 (27.3%)
Part 1: Cohort 2- One CYP3A5*1 Allele—0/12 (0%)0/12 (0%)
Part 1: Cohort 3- Two CYP3A5*1 Alleles—0/12 (0%)0/12 (0%)
Part 1: Cohort 4 - No CYP3A5*1 Alleles—0/12 (0%)3/12 (25%)
Part 2: Cohort 1- No CYP3A5*1 Alleles—0/11 (0%)2/11 (18.2%)
Part 2: Cohort 3- Two CYP3A5*1 Alleles—0/12 (0%)1/12 (8.3%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPart 1: Cohort 1- No CYP3A5*1 AllelesPart 1: Cohort 2- One CYP3A5*1 AllelePart 1: Cohort 3- Two CYP3A5*1 AllelesPart 1: Cohort 4 - No CYP3A5*1 AllelesPart 2: Cohort 1- No CYP3A5*1 AllelesPart 2: Cohort 3- Two CYP3A5*1 Alleles
PollakiuriaRenal and urinary disorders0/110/120/122/120/110/12
Dry mouthGastrointestinal disorders1/110/120/120/121/110/12
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/110/120/120/121/110/12
FlatulenceGastrointestinal disorders1/110/120/121/120/110/12
PainGeneral disorders1/110/120/120/120/110/12
PolyuriaRenal and urinary disorders1/110/120/120/120/110/12
Throat irritationRespiratory, thoracic and mediastinal disorders1/110/120/120/120/110/12
HyperhidrosisSkin and subcutaneous tissue disorders1/110/120/120/120/110/12
Hot flushVascular disorders1/110/120/120/120/110/12
Abdominal pain upperGastrointestinal disorders0/110/120/120/121/110/12

Baseline characteristics

Safety analysis set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Part 1 and Part 2: Cohort 1 -No CYP3A5*1 AllelesPart 1: Cohort 2 - One CYP3A5*1 AllelePart 1 and 2: Cohort 3 - Two CYP3A5*1 AllelesPart 1: Cohort 4 - No CYP3A5*1 AllelesTotal
Mean37.3 ± 9.738.3 ± 10.434.6 ± 11.448.2 ± 639.6 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 and Part 2: Cohort 1 -No CYP3A5*1 AllelesPart 1: Cohort 2 - One CYP3A5*1 AllelePart 1 and 2: Cohort 3 - Two CYP3A5*1 AllelesPart 1: Cohort 4 - No CYP3A5*1 AllelesTotal
Female20114
Male912111143
08

Study locations

1 site
  • Pfizer New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Publications

  • Vourvahis M, McFadyen L, Nepal S, Valluri SR, Fang A, Fate GD, Wood LS, Marshall JC, Chan PLS, Nedderman A, Haynes J, Savage ME, Clark A, Smith KY, Heera J. No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects. J Clin Pharmacol. 2019 Jan;59(1):139-152. doi: 10.1002/jcph.1306. Epub 2018 Sep 7. PubMed 30192390 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Mar 2016, 4 months.

Results were first posted in Apr 2017, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2015
First posted
Dec 9, 2015
StartActual
Nov 6, 2015
Primary completionActual
Mar 26, 2016
CompletionActual
Mar 26, 2016
Results first posted
Apr 17, 2017
Last update
Apr 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02625207
Lead sponsor
ViiV Healthcare
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Dec 9, 2015
Start date
Nov 6, 2015
Primary completion
Mar 26, 2016
Completion
Mar 26, 2016
Results posted
Apr 17, 2017
Last update
Apr 17, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Maraviroc · Cobicistat mixture with darunavir

Start the discussion